GLORIOSO III JOSEPH C,COHEN JUSTUS,MIYAGAWA YOSHITAKA,KRISKY DAVID,WECHUCK JAMES,WOLFE DARREN
申请号：
IN201617001752
公开号：
IN201617001752A
申请日:
2016.01.18
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
In one embodiment, the invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non- complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector.
